ArticleWiener klinische Wochenschrift2026
Tumor-induced osteomalacia caused by fibroblast growth factor 23 excess : Delayed diagnosis resulting from overlooked hypophosphatemia-A case report.
Article in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-induced osteomalacia is a rare acquired disorder of phosphate metabolism caused by fibroblast growth factor (FGF)23-secreting mesenchymal tumors. We report the case of a 39-year-old man with a 3-year history of progressive musculoskeletal pain, in whom unrecognized hypophosphatemia led to misdiagnoses, including osteoporosis and inflammatory musculoskeletal disorders, and consequently, to inappropriate management. Biochemical evaluation revealed persistent hypophosphatemia, elevated alkaline phosphatase levels, secondary hyperparathyroidism, and markedly increased serum FGF23 levels. Gallium-68 DOTATATE positron emission tomography/computed tomography (PET/CT) identified a phosphaturic mesenchymal tumor located in the medial condyle of the right distal femur, which was subsequently confirmed histopathologically after surgical excision. Following surgery, serum phosphorus and FGF23 levels rapidly normalized, accompanied by significant clinical improvement. This case highlights unrecognized hypophosphatemia as a critical yet preventable cause of diagnostic delay and emphasizes the importance of routine serum phosphate assessment to avoid misdiagnosis and enable timely curative treatment.
Indexed as
Identifiers
42773194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.